PAW Volume 7, Issue 1
2 Belsomra (R): A Novel Dual Orexin Receptor Antagonist for the Treatment of Insomnia
CE Included
Shane Bogusz, PharmD Candidate 2017; Steven Blake, PharmD Candidate 2018; Michaela Wolford, PharmD Candidate 2018; Victoria Cho, PharmD Candidate 2017; Manoranjan D'Souza, M.D., Ph.D.
8 PCSK9 Inhibitors: A Novel Class of Pharmacotherapy for Hypercholesterolemia
CE Included
Angela Chu, PharmD Candidate 2017; Austin Hilverding, PharmD Candidate 2018; Elizabeth Kramer, PharmD Candidate 2018; Brendan Rasor, PharmD Candidate 2017; Boyd Rorabaugh BS, M.S., Ph.D.
13 Programmed Death Pathway Inhibition: Emerging Therapeutic Options for Treatment of Advanced or Refractory Cancers
Katherine Elsass, PharmD Candidate 2017; Morgan Homan, PharmD Candidate 2018; Jana Randolph, PharmD Candidate 2018; Brendan Rasor, PharmD Candidate 2017; David Kinder BS, M.S., Ph.D.
18 Improving Healthcare Costs and Patient Outcomes Across Healthcare Professions
Hannah Lamb, PharmD Candidate 2018; Jourdan Uljaki, PharmD Candidate 2018; Paige Torbet, PharmD Candidate 2018; Isabel Cwikla, PharmD Candidate 2018; Rebecca Worden, PharmD Candidate 2017; Michael Rush, PharmD, BCACP, CDE, TTS
22 The Effect of CYP3A5 Polymorphism on Kidney Transplnt Recipients Given Tacromilus
Samia Alam, PharmD Candidate 2018; Sunitha Jones, PharmD Candidate 2018; Haval Norman, PharmD Candidate 2018; Brian Heilbronner, PharmD Candidate 2017; Yousif Rojeab, BS, Ph.D.
28 Health Risks and Emerging Trends with the Use of Electronic Cigarettes
Lucy Wagala, PharmD Candidate 2017; Austin Hopkins, PharmD Candidate 2018; Natalie Lennartz, PharmD Candidate 2017; Brian Heilbronner, PharmD Candidate 2017; Brittany L. Long, PharmD, TTS; Natalie DiPietro Mager, PharmD, MPH
CE Included
Shane Bogusz, PharmD Candidate 2017; Steven Blake, PharmD Candidate 2018; Michaela Wolford, PharmD Candidate 2018; Victoria Cho, PharmD Candidate 2017; Manoranjan D'Souza, M.D., Ph.D.
8 PCSK9 Inhibitors: A Novel Class of Pharmacotherapy for Hypercholesterolemia
CE Included
Angela Chu, PharmD Candidate 2017; Austin Hilverding, PharmD Candidate 2018; Elizabeth Kramer, PharmD Candidate 2018; Brendan Rasor, PharmD Candidate 2017; Boyd Rorabaugh BS, M.S., Ph.D.
13 Programmed Death Pathway Inhibition: Emerging Therapeutic Options for Treatment of Advanced or Refractory Cancers
Katherine Elsass, PharmD Candidate 2017; Morgan Homan, PharmD Candidate 2018; Jana Randolph, PharmD Candidate 2018; Brendan Rasor, PharmD Candidate 2017; David Kinder BS, M.S., Ph.D.
18 Improving Healthcare Costs and Patient Outcomes Across Healthcare Professions
Hannah Lamb, PharmD Candidate 2018; Jourdan Uljaki, PharmD Candidate 2018; Paige Torbet, PharmD Candidate 2018; Isabel Cwikla, PharmD Candidate 2018; Rebecca Worden, PharmD Candidate 2017; Michael Rush, PharmD, BCACP, CDE, TTS
22 The Effect of CYP3A5 Polymorphism on Kidney Transplnt Recipients Given Tacromilus
Samia Alam, PharmD Candidate 2018; Sunitha Jones, PharmD Candidate 2018; Haval Norman, PharmD Candidate 2018; Brian Heilbronner, PharmD Candidate 2017; Yousif Rojeab, BS, Ph.D.
28 Health Risks and Emerging Trends with the Use of Electronic Cigarettes
Lucy Wagala, PharmD Candidate 2017; Austin Hopkins, PharmD Candidate 2018; Natalie Lennartz, PharmD Candidate 2017; Brian Heilbronner, PharmD Candidate 2017; Brittany L. Long, PharmD, TTS; Natalie DiPietro Mager, PharmD, MPH
pharmacy_and_wellness_review_vol_7_iss_1_winter_2016_rev_date_6_2_2016.pdf | |
File Size: | 2577 kb |
File Type: |